Lanadelumab News
Lanadelumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Lanadelumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
- Evidence level: L1
- Predicted indications (20):
- C1 inhibitor deficiency (100.0%)
- hereditary angioedema with C1Inh deficiency (100.0%)
- serpinopathy with toxic serpin polymerization (100.0%)
- pancreatitis (99.9%)
- hereditary angioedema (99.6%)
- pseudo-von Willebrand disease (99.5%)
- primary release disorder of platelets (99.5%)
- immune-mediated necrotizing myopathy (99.3%)
- Glanzmann thrombasthenia (99.3%)
- antisynthetase syndrome (99.3%)
- focal myositis (99.3%)
- Scott syndrome (99.1%)
- idiopathic eosinophilic myositis (99.1%)
- inflammatory myopathy with abundant macrophages (99.1%)
- Peyronie disease (99.0%)
- alcoholic cardiomyopathy (98.8%)
- symptomatic form of hemophilia in female carriers (98.7%)
- familial apolipoprotein C-II deficiency (98.6%)
- bleeding diathesis due to a collagen receptor defect (98.3%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (98.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.